Groupe Hospitalo-Universitaire Paris Psychiatrie & Neurosciences
Paris, France
Location status: Recruiting
NCT Number: NCT06361160
Approximately 1% of the general population will be affected by schizophrenia over the course of their lives, with life expectancy being reduced by 20 years on average and quality of life being severely diminished in affected individuals. One third of patients suffering from schizophrenia will evolve towards a resistant form of the disease, amongst which many will suffer from auditory-verbal hallucinations (AVH) that current therapeutic approaches struggle to alleviate. Previous work from our team has demonstrated the possibility of robustly inferring the periods of occurrence of AVH from fMRI data, paving the way for the development of a closed-loop neuromodulation system comprised of an electrode array positioned in Broca's area, which would detect AVH in real time, and effector electrodes which would stimulate the temporo-parietal cortex to interrupt them. The aim of this project is to assess the feasibility of this system. To do so, we will first test the ability of transcranial magnetic stimulation of the "continuous theta burst" (cTBS) type, applied at the time of AVH onset, to reduce their duration and intensity, and assess whether this is associated with therapeutic response to the current gold standard rTMS protocol for AVH reduction through neuroplasticity induction. Demonstrating the feasibility of acute suppression of AVH by cortical neurostimulation is an essential element in the feasibility of a closed-loop reactive neuromodulation system.
The research project comprises two phases:
-Phase 1: randomized controlled clinical trial (1 weekly session per patient over 12 weeks: 6 active stimulation sessions and 6 sham sessions) evaluating the phasic effects of rTMS on AVHs as they appear during the sessions.
Phase 2: open-label study offering patients a routine rTMS protocol which has demonstrated its effects on AVH (10 TMS sessions over one workweek - twice daily with 1-hour intervals, MULTIMODHAL study, NCT01373866).
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Paris, France
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Active rTMS (continuous theta burst, cTBS) applied to the temporo-parietal junction (TPJ) at the onset of the Auditory Verbal Hallucinations (AVH).
Other names: Active TMS
Sham rTMS (continuous theta burst, cTBS) applied to the temporo-parietal junction (TPJ) during the onset of the Auditory Verbal Hallucinations (AVH).
An electrical stimulator is synchronised with the magnetic stimulation to recreate the tactile sensation and the coils emits the same noise during sham stimulation as in the active configuration, making it impossible to distinguish between active and placebo magnetic stimulation.
Other names: Sham TMS
Time frame: During the intervention of Phase 1 (for each active or sham TMS session)
The primary endpoint is the reduction in the duration of AVH (in seconds) during active phasic stimulation sessions compared to sham sessions. Participants will press a button when an AVH occurs (starting the intervention) and press another when the AVH disappears. This allows for the recording of the duration of the AVHs.
Time frame: At baseline (before Phase 1), before the intervention of Phase 2 (Day 0, two weeks after the end of Phase 1), after the intervention of Phase 2 (Day 15, Month 1, Month 3, Month 6, Month 12)
An evaluation of the following clinical measures will take place : AHRS, CGI, Visual analog scale for AVH intensity and frequency, GAF and PANSS.
Time frame: Through study completion, an average of 2 years
Reduction in duration and/or intensity of HAV (in seconds) during active phasic stimulation sessions compared to sham sessions (phase 1) among TMS responders and non-responders in phase 2 (response: decrease in pre/post AHRS score >25%).
Time frame: During the intervention of Phase 1 (for each active or sham TMS session)
Phase 1 At the end of each active or sham cTBS train, the computer screen will display an 5-point Likert Scale, through which the patient will have to report AVH-intensity before the session can continue.
Contact information is provided by the study sponsor or research team.
Fabien Vinckier, MD, PhD
CONTACT
(0) 1 45 65 84 52 ext. +(33)
Philippe Domenech, MD, PhD
CONTACT
(0)1 49 81 22 01 ext. +(33)
Centre Hospitalier St Anne
Other
Reduction of Auditory-Verbal Hallucinations in Schizophrenia Through Cortical Neuromodulation: Towards a Closed-loop System
Acronym: HALLUSTIM
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06456983
Mental Disorders, Schizophrenia
Aachen, Germany
View Trial DetailsNCT06672588
Mental Disorders, Psychotic Disorders
Vancouver, British Columbia, Canada
View Trial DetailsNCT06505668
Arrhythmias, Cardiac, Cardiac Conduction System Disease
Bhubaneswar, Odisha, India
View Trial DetailsNCT07047651
Mental Disorders, Schizophrenia
Athens, Greece
View Trial Details